Carcinogenicity OECD 453

Altogen Labs provides combined chronic toxicity and carcinogenicity studies per OECD test guidelines No. 435, ensuring all assessments meet the highest standards for regulatory compliance and scientific integrity. Altogen Labs test procedures provide essential data for evaluating the potential long-term health risks of chemical exposure, contributing to risk assessment, regulatory decision-making, and the establishment of safe exposure thresholds for human health. The combined study approach enhances efficiency by simultaneously assessing chronic toxicity and carcinogenicity within a single protocol, thereby reducing time, cost, and the number of test animals required. The primary objective of chronic toxicity and carcinogenicity studies at Altogen Labs is to assess the potential toxic effects of repeated chemical exposure over an extended period, up to the entire lifespan of the test species. Altogen Labs utilized these studies to identify carcinogenic properties, target organs, toxic accumulation potential, and the relationship between dose and response. These studies are also used to determine the no-observed-adverse-effect level (NOAEL) and, in cases of non-genotoxic carcinogens, the benchmark dose (BMD) for tumor development. Additionally, the studies are also utilized to evaluate time-to-onset of neoplasms, chronic toxicity markers, and mode-of-action hypotheses for tumorigenesis.

Initial Considerations

Prior to the initiation of a chronic toxicity and carcinogenicity study, Altogen Labs conducts an exhaustive evaluation of all pertinent information on the test substance, including its chemical identity, molecular structure, physicochemical properties, and prior toxicological data. A thorough literature review and analysis of in silico, in vitro, and in vivo data facilitate informed study design decisions. Emphasis is placed on clarifying the mode of action of the test substance, as this distinction significantly influences dose selection, study duration, and interpretive outcomes. Short-term toxicity data, including results from repeated-dose 28-day and 90-day studies, serve as a foundation for dose-range selection and study optimization. Furthermore, appropriate statistical methodologies for analyzing survival, tumor incidence, and systemic toxicity endpoints are established before study initiation to ensure robust and interpretable results.

Principle of the Test

The study design consists of two parallel investigative phases: a chronic toxicity phase and a carcinogenicity phase. The test substance is typically administered via oral ingestion, either through diet, drinking water, or gavage; however, dermal and inhalation exposure models are also employed when relevant to anticipated human exposure scenarios. The chronic toxicity phase spans twelve months and aims to elucidate cumulative toxicological effects, identify dose-dependent biological responses, and characterize organ-specific toxicity. The carcinogenicity phase extends to twenty-four months to allow sufficient latency for neoplastic lesion development and tumor progression. Clinical observations, hematological and biochemical analyses, and histopathological evaluations are systematically conducted to generate a comprehensive toxicological profile.

Selection of Test Species

At Altogen Labs, rodents, particularly rats and mice, are the preferred test species due to their well-characterized physiology, genetic uniformity, and susceptibility to tumorigenesis. Their relatively short lifespan, extensive historical control data, and established relevance in toxicological research further support their selection. When warranted by specific human health considerations, non-rodent species may be utilized, following the principles outlined in OECD Test Guideline 409. All test animals are required to be young, healthy, and sourced from reputable laboratory suppliers. Female subjects are selected to be nulliparous and non-pregnant to eliminate confounding hormonal influences.

Preparation of Animals

At Altogen Labs, rigorous standards of health and genetic integrity are upheld to ensure the suitability of all test animals prior to study initiation. Each animal undergoes an acclimation period of no less than seven days to facilitate physiological stabilization in its new environment. Only healthy, experimentally naïve animals are selected for study inclusion. In rodent studies, dosing is initiated as early as possible post-weaning, preferably before the animals reach eight weeks of age.

All test animals are systematically characterized by species, strain, sex, age, and body weight, with initial weight variation within each sex restricted to ±20% of the mean. To mitigate selection bias, animals are randomly assigned to control and treatment groups. Any statistically significant deviations in body weight distribution between groups are corrected through re-randomization. Each animal is assigned a unique identifier, which is maintained throughout the study to ensure traceability and data integrity.

Housing conditions are stringently controlled to maintain environmental consistency. Temperature is maintained at 22°C (±3°C), and relative humidity is regulated between 50–60%. A 12-hour light/dark cycle is enforced to preserve circadian rhythm stability. Animals are housed either individually or in small, sex-segregated groups to minimize social stress. Nutritionally optimized diets are provided, with all feed undergoing routine analytical verification to confirm the absence of contaminants such as pesticide residues, heavy metals, and mycotoxins that could potentially confound study outcomes.

Procedure

Altogen Labs implements stringent procedural controls to ensure the integrity, reproducibility, and regulatory compliance of all chronic toxicity and carcinogenicity studies. Test animals are randomized into dose groups to maintain statistical robustness and eliminate selection bias. The test substance is administered daily in a controlled manner, with oral administration via diet, drinking water, or gavage being the most common route. Inhalation studies require specialized exposure chambers to deliver consistent aerosolized concentrations, while dermal studies involve precisely measured topical application to simulate occupational or environmental exposure scenarios.

Throughout the study duration, animals are monitored continuously for clinical signs of toxicity. Parameters such as body weight, food and water consumption, and general health status are recorded weekly for the first thirteen weeks and monthly thereafter. Neurological and sensory assessments, including grip strength and motor activity testing, are conducted if prior toxicological data indicate potential neurotoxic effects. Ophthalmological examinations are performed at baseline and at study termination. Interim necropsies are conducted at predetermined intervals to assess early pathological changes, while hematological and biochemical analyses at three, six, and twelve months provide key insights into systemic toxicity.

Animal Selection and Grouping

Altogen Labs utilizes both male and female rodents in our studies to achieve comprehensive biological and statistical evaluations. Each dose group and concurrent control group for carcinogenicity studies includes a minimum of 50 animals per sex, allowing for robust statistical analysis. When necessary, additional animals may be allocated to lower dose groups to enhance the statistical power of key estimates. For chronic toxicity studies, we employ at least 10 animals per sex per dose group, with additional subjects incorporated as needed for specialized analyses such as hematological assessments in mice.

Interim Kills, Satellite Groups, and Sentinel Animals

To assess the progression of toxicological effects, interim sacrifices may be performed, typically at the six-month mark, particularly in the chronic toxicity phase. If sufficient historical data is available, these interim assessments may be deemed unnecessary. Animals utilized in the chronic toxicity phase contribute interim data to the carcinogenicity study, thereby optimizing animal use.

Dose Administration and Selection

All studies at Altogen Labs employ a minimum of three dose levels along with a concurrent control group, with dose selection based on prior toxicological and toxicokinetic data to meet regulatory requirements. In chronic toxicity assessments, a single high-dose study (≥1000 mg/kg/day) may be conducted when preliminary data indicate a low likelihood of adverse effects.

The highest dose is carefully selected to identify target organ toxicity while preventing undue suffering, excessive morbidity, or mortality—typically characterized by a moderate reduction (~10%) in body weight gain. Lower dose levels are determined based on expected dose-response relationships, metabolic and toxicokinetic considerations, and relevance to human exposure levels. Dose spacing follows scientifically validated principles, generally utilizing two- to four-fold intervals, with justifications provided for deviations beyond this range. Control groups receive either no treatment or the vehicle at the highest administered volume. If the test compound is diet-based and results in significantly reduced food intake due to palatability, a pair-fed control group may be incorporated to account for nutritional variables.

Routes of Administration

The route of administration is selected based on the physicochemical characteristics of the test compound and its primary human exposure pathway. Oral administration via dietary incorporation, drinking water, or gavage is the most frequently utilized method due to its practical applicability and relevance to human exposure. Inhalation studies require specialized exposure chambers to maintain controlled aerosolized concentrations, ensuring consistent respiratory uptake. Dermal exposure studies involve precisely measured topical application to simulate occupational and environmental exposure conditions. Regardless of the chosen route, Altogen Labs ensures meticulous formulation stability testing and homogeneity assessments are conducted to guarantee uniform test substance delivery throughout the study duration.

Study Duration

The chronic toxicity phase of the study is typically conducted over a twelve-month period, while the carcinogenicity phase extends to twenty-four months to encompass the entire tumorigenesis process. For specific mouse strains with shorter life expectancies, an eighteen-month study duration may be implemented. The highest administered dose is carefully selected to induce detectable toxic effects without precipitating undue morbidity or mortality. Dose selection is guided by metabolic saturation kinetics, dose-response inflection points, and anticipated human exposure levels. At least three test dose groups and a concurrent control group are included, with vehicle controls utilized as appropriate to account for formulation-related variables.

Observations (Chronic Toxicity Phase)

Animals enrolled in the chronic toxicity phase undergo detailed daily clinical evaluations to detect deviations in physiological function, behavior, and overall health. Key observational endpoints include changes in skin, fur, mucous membranes, and autonomic activity, along with indicators of neuromuscular function such as tremors, convulsions, and coordination deficits. Systemic toxicity is assessed through weight progression trends, food and water intake records, and evidence of metabolic disturbances. Periodic hematological, biochemical, and urinalysis assessments allow for the detection of hepatotoxic, nephrotoxic, and hematopoietic perturbations.

To evaluate systemic toxicity and organ-specific damage, comprehensive hematological and clinical biochemistry assessments are performed at three, six, and twelve months. Blood samples are collected from a designated anatomical site, such as the retro-orbital sinus or tail vein, and analyzed for a range of hematological parameters, including total and differential leukocyte counts, erythrocyte counts, hemoglobin concentration, hematocrit values, platelet counts, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), and clotting parameters such as prothrombin time and activated partial thromboplastin time.

Clinical biochemistry analyses provide insights into hepatic and renal function, metabolic integrity, and systemic homeostasis. Key parameters include serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), total bilirubin, and gamma-glutamyl transferase (GGT) to assess hepatocellular and hepatobiliary function. Renal parameters, including blood urea nitrogen (BUN), creatinine, and electrolyte levels, are measured to evaluate nephrotoxicity. Glucose, cholesterol, total protein, albumin, and calcium concentrations are analyzed to monitor metabolic status and homeostatic equilibrium. Additional markers, such as lactate dehydrogenase (LDH) and specific hormone levels, may be assessed depending on the toxicological profile of the test compound.

Urinalysis is performed to detect renal and metabolic abnormalities, with assessments including urine pH, specific gravity, proteinuria, glucosuria, ketonuria, and microscopic examination of urinary sediments. Hematuria and leukocyturia are indicative of renal or systemic pathology and are investigated further through histopathological evaluation. Necropsies conducted at the end of the chronic toxicity phase provide histopathological insights into organ-specific toxic effects and allow early detection of cellular alterations suggestive of carcinogenic potential.

Observations (Carcinogenicity Phase)

In the carcinogenicity phase, comprehensive surveillance is maintained to monitor the onset and progression of neoplastic lesions. Tumor development is documented in terms of anatomical location, size, consistency, and histopathological classification. Early indicators of neoplasia, such as localized hyperplasia or dysplasia, are closely monitored, as are secondary pathological changes associated with tumor burden, including cachexia and organ compression. Survival trends across dose groups are carefully analyzed to distinguish substance-related mortality from spontaneous age-related decline. Upon study completion, all surviving animals undergo gross necropsy and extensive histopathological assessment to confirm neoplastic findings and evaluate potential systemic carcinogenic effects. Tumor incidence data are statistically analyzed to establish dose-response relationships and assess potential genotoxic versus non-genotoxic mechanisms of carcinogenesis.

Necropsy and Pathological Evaluation

Altogen Labs ensures that at study termination, all surviving animals undergo a full necropsy and comprehensive histopathological assessment. Gross pathological examination of external surfaces, orifices, and internal organs is conducted to document macroscopic abnormalities. Organ weights are meticulously recorded for key tissues, including the brain, heart, liver, kidneys, spleen, adrenals, testes, ovaries, thyroid, and uterus. Histopathological evaluations focus on the identification of neoplastic and non-neoplastic lesions, with particular emphasis on organs exhibiting prior toxicological effects. Findings are systematically classified and correlated with macroscopic observations to construct a detailed toxicological profile.

Data Reporting for Carcinogenicity and Chronic Toxicity

All Altogen Labs study data is meticulously recorded and analyzed to ensure compliance with regulatory expectations. The final report includes detailed individual animal data, summarizing survival outcomes, clinical signs, hematological and biochemical findings, necropsy results, and histopathological evaluations. Comprehensive statistical analyses are conducted to assess dose-response trends, survival rates, and carcinogenic potential. Historical control data are referenced where applicable to provide context for observed findings. The final report also includes an in-depth discussion of toxicological significance, mode-of-action considerations, and potential human health implications.

Regulatory Compliance and Ethical Considerations

Altogen Labs adheres rigorously to OECD Test Guideline 453 for chronic toxicity and carcinogenicity studies. Our research complies with Good Laboratory Practice (GLP) standards and conforms to stringent animal welfare regulations. Humane endpoints and predefined euthanasia criteria are implemented to minimize animal distress while maximizing scientific validity.

Request a Quote

Please provide details about your safety assessment study, including the phase of development, route of administration, species, and duration. We offer expert solutions and are happy to discuss our services, methods, and technologies.